Home » Stocks » Aquestive Therapeutics

Aquestive Therapeutics, Inc. (AQST)

Stock Price: $4.61 USD 0.03 (0.66%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 154.82M
Revenue (ttm) 48.73M
Net Income (ttm) -68.05M
Shares Out 33.58M
EPS (ttm) -2.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $4.61
Previous Close $4.58
Change ($) 0.03
Change (%) 0.66%
Day's Open 4.61
Day's Range 4.50 - 4.70
Day's Volume 494,599
52-Week Range 1.41 - 10.00

More Stats

Market Cap 154.82M
Enterprise Value 184.25M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 33.58M
Float 27.65M
EPS (basic) -2.51
EPS (diluted) -2.47
FCF / Share -1.69
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.63M
Short Ratio 1.07
Short % of Float 8.38%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.18
PB Ratio n/a
Revenue 48.73M
Operating Income -53.46M
Net Income -68.05M
Free Cash Flow -56.59M
Net Cash -29.43M
Net Cash / Share -0.88
Gross Margin 66.18%
Operating Margin -109.69%
Profit Margin -139.60%
FCF Margin -116.12%
ROA -50.44%
ROE -3,347.45%
ROIC -86.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$17.50*
(279.61% upside)
Low
8.00
Current: 4.61
High
31.00
Target: 17.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue52.6167.4366.9251.79
Revenue Growth-21.98%0.77%29.22%-
Gross Profit32.2546.4447.1035.41
Operating Income-52.67-48.94-0.11-0.95
Net Income-66.25-61.38-8.94-9.60
Shares Outstanding25.3620.73121119
Earnings Per Share-2.61-2.96-0.09-0.10
Operating Cash Flow-60.21-12.995.82-8.18
Capital Expenditures-0.66-1.82-2.07-0.98
Free Cash Flow-60.87-14.823.76-9.15
Cash & Equivalents49.3360.6017.389.21
Total Debt60.3447.2045.5138.65
Net Cash / Debt-11.0113.40-28.13-29.44
Assets78.4886.8543.1239.39
Liabilities84.6076.7769.6196.59
Book Value-6.1210.08-68.60-57.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aquestive Therapeutics, Inc.
Country United States
Employees 232
CEO Keith J. Kendall

Stock Information

Ticker Symbol AQST
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AQST
IPO Date July 25, 2018

Description

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.